IncobotulinumtoxinA treatment of facial nerve palsy after neurosurgery.

Abstract

BACKGROUND:

This study evaluates the effect of incobotulinumtoxinA in the acute and chronic phases of facial nerve palsy after neurosurgical interventions.

METHODS:

Patients received incobotulinumtoxinA injections (active treatment group) or standard rehabilitation treatment (control group). Functional efficacy was assessed using House-Brackmann, Yanagihara System and Sunnybrook Facial Grading scales, and Facial Disability Index self-assessment.

RESULTS:

Significant improvements on all scales were seen after 1month of incobotulinumtoxinA treatment (active treatment group, р<0.05), but only after 3months of rehabilitation treatment (control group, р<0.05). At 1 and 2years post-surgery, the prevalence of synkinesis was significantly higher in patients in the control group compared with those receiving incobotulinumtoxinA treatment (р<0.05 and р<0.001, respectively).

CONCLUSIONS:

IncobotulinumtoxinA treatment resulted in significant improvements in facial symmetry in patients with facial nerve injury following neurosurgical interventions. Treatment was effective for the correction of the compensatory hyperactivity of mimic muscles on the unaffected side that develops in the acute period of facial nerve palsy, and for the correction of synkinesis in the affected side that develops in the long-term period. Appropriate dosing and patient education to perform exercises to restore mimic muscle function should be considered in multimodal treatment.

• Authors: Mihail A Akulov, Ol'ga R Orlova, Aleksandra S Orlova, Dmitrij J Usachev, Vadim N Shimansky, Sergey V Tanjashin, Svetlana E Khatkova, Anna V Yunosha-Shanyavskaya
• Journal: Journal of the neurological sciences (J Neurol Sci) Vol. 381 Pg. 130-134 (Oct 15 2017) ISSN: 1878-5883 [Electronic] Netherlands
• PMID: 28991664 (Publication Type: Journal Article, Randomized Controlled Trial)
• Copyright: Copyright © 2017 Elsevier B.V. All rights reserved.

Chemical References

• Neuromuscular Agents
• Botulinum Toxins, Type A
• incobotulinumtoxinA

Topics

• Acute Disease
• Botulinum Toxins, Type A (therapeutic use)
• Chronic Disease
• Disability Evaluation
• Facial Nerve Injuries (drug therapy, epidemiology, physiopathology, rehabilitation)
• Facial Paralysis (drug therapy, epidemiology, physiopathology, rehabilitation)
• Female
• Humans
• Male
• Middle Aged
• Neuromuscular Agents (therapeutic use)
• Neurosurgical Procedures
• Postoperative Complications (drug therapy, epidemiology, rehabilitation)
• Prevalence
• Single-Blind Method
• Synkinesis (drug therapy, epidemiology, physiopathology)
• Traction
• Treatment Outcome